Advanced NSCLC patients with EGFR mutations occurring in exons 18–21 can dramatically benefit from EGFR tyrosine kinase inhibitors (TKIs) out of other drug therapies.6, 7. This evidence concerns the gene EGFR and non-small cell lung carcinoma.